The recently developed monomeric nonionic contrast medium iomeprol was
tested in concentrations of 150, 200, 250, 300, 350, and 400 mgI/ml i
n open multicentre Phase III studies. The clinical testing was perform
ed in a nonselected patient population (n = 4811); a total of 15 850 i
njections of the contrast medium was used. All the common radiological
methods were used in the study, which was performed in over 150 centr
es. The contrast density was evaluated as good or satisfactory in 99%
of the total patient population. Relevant heat and pain sensations occ
urred rarely; severe heat and pain were reported only 1.25% and 0.3% o
f the patients, respectively.